(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 April 2008 (10.04.2008)

PCT

(10) International Publication Number
WO 2008/041118 A2

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 19/10* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/IB2007/002976

(22) International Filing Date:
26 September 2007 (26.09.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/828,162 4 October 2006 (04.10.2006) US
60/969,083 30 August 2007 (30.08.2007) US

(71) Applicant *(for all designated States except US)*: **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BI, Feng** [CN/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121 (US). **DIDIUK, Mary, Theresa** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **GRIFFITH, David, Andrew** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **GUZMAN-PEREZ, Angel** [MX/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **LIU, Kevin Kun-Chin** [US/US]; Pfizer Global Research & Development, 10777 Science Center Drive, San Diego, CA 92121 (US). **WALKER, Daniel, Patrick** [US/US]; Pfizer Global Research & Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US).


(74) Agents: **FULLER, Grover, F., Jr.** et al.; c/o GEORGE, Nancy, McGraw, Pfizer Inc. MS8260-1615, Eastern Point Road, Groton, CT 06340 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

(54) **Title:** PYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS



(I)

(57) **Abstract:** The present invention is directed to novel pyrido[4,3-</]pyrimidin-4(3H)-one derivatives and pharmaceutically acceptable salts thereof of structural formula I wherein the variables R^1, R^2, R^3, R^4 and R^5 are as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget' s disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.

WO 2008/041118 A2